SG11201506647SA - Bispecific bivalent scfv-fc molecules - Google Patents

Bispecific bivalent scfv-fc molecules

Info

Publication number
SG11201506647SA
SG11201506647SA SG11201506647SA SG11201506647SA SG11201506647SA SG 11201506647S A SG11201506647S A SG 11201506647SA SG 11201506647S A SG11201506647S A SG 11201506647SA SG 11201506647S A SG11201506647S A SG 11201506647SA SG 11201506647S A SG11201506647S A SG 11201506647SA
Authority
SG
Singapore
Prior art keywords
molecules
bivalent scfv
bispecific bivalent
bispecific
scfv
Prior art date
Application number
SG11201506647SA
Other languages
English (en)
Inventor
Luis G Borges
Patrick A Baeuerle
Wei Yan
Mark L Michaels
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201506647SA publication Critical patent/SG11201506647SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201506647SA 2013-03-15 2014-03-14 Bispecific bivalent scfv-fc molecules SG11201506647SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791424P 2013-03-15 2013-03-15
PCT/US2014/029253 WO2014144722A2 (en) 2013-03-15 2014-03-14 BISPECIFIC-Fc MOLECULES

Publications (1)

Publication Number Publication Date
SG11201506647SA true SG11201506647SA (en) 2015-09-29

Family

ID=50489434

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506647SA SG11201506647SA (en) 2013-03-15 2014-03-14 Bispecific bivalent scfv-fc molecules

Country Status (21)

Country Link
US (5) US20140302037A1 (es)
EP (1) EP2970477B1 (es)
JP (2) JP6535654B2 (es)
KR (1) KR20150139531A (es)
CN (1) CN105229031A (es)
AP (1) AP2015008773A0 (es)
AU (1) AU2014228829B2 (es)
BR (1) BR112015023431A2 (es)
CA (1) CA2902961C (es)
CL (1) CL2015002756A1 (es)
CR (1) CR20150573A (es)
EA (1) EA201591814A1 (es)
HK (1) HK1214275A1 (es)
IL (1) IL241354A0 (es)
MA (1) MA38400A1 (es)
MX (2) MX2015012187A (es)
PE (1) PE20151998A1 (es)
PH (1) PH12015502083A1 (es)
SG (1) SG11201506647SA (es)
TN (1) TN2015000379A1 (es)
WO (1) WO2014144722A2 (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201403444UA (en) * 2011-12-21 2014-07-30 Amgen Inc Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
RU2650868C2 (ru) * 2012-07-13 2018-04-17 Займворкс Инк. Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AU2014236769B2 (en) * 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
DK2992020T3 (da) 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
EP3074424A4 (en) 2013-11-27 2017-06-14 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
NZ721309A (en) 2013-12-17 2019-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
JP6894702B2 (ja) * 2014-05-13 2021-06-30 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107206072B (zh) 2014-11-20 2022-01-21 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD-1轴结合拮抗剂的组合疗法
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
AU2016246457B2 (en) 2015-04-06 2020-10-15 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
MA43197A (fr) 2015-04-17 2018-09-19 Amgen Res Munich Gmbh Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016182064A1 (ja) * 2015-05-13 2016-11-17 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
BR112017024899A2 (pt) 2015-05-21 2018-11-13 Harpoon Therapeutics, Inc. proteínas de ligação trispecíficas e métodos de uso.
WO2017011413A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CR20180105A (es) * 2015-08-17 2018-06-12 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP3356410B1 (en) * 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
CN116789841A (zh) 2015-10-25 2023-09-22 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
US10752686B2 (en) * 2015-10-30 2020-08-25 Zonhon Biopharma Institute Inc. Bispecific antibody binding to human CD26 and human CD3, production method therefor and use thereof
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
TWI748984B (zh) 2016-02-03 2021-12-11 德商安美基研究（慕尼黑）公司 Bcma及cd3雙特異性t細胞嚙合抗體構築體
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CA3016563A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN108884170A (zh) * 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
SI3433280T1 (sl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag S proteazo aktivirane bispecifične molekule celic T
PL3443006T3 (pl) 2016-04-13 2024-01-29 Sanofi Trójswoiste i/lub triwalentne białka wiążące
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
EA201892693A1 (ru) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
CN115925780A (zh) 2016-07-22 2023-04-07 美国安进公司 含有Fc的蛋白的纯化方法
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原結合タンパク質
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MA44670B1 (fr) * 2017-03-17 2023-11-30 Sanofi Sa Protéines de liaison trispécifiques et/ou trivalentes
EP3618864A1 (en) 2017-05-05 2020-03-11 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EA202090739A1 (ru) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. Белки, связывающие антиген созревания в-клеток
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
JP2021506310A (ja) 2017-12-22 2021-02-22 アルゲン−エックス ビーブイビーエー 二重特異性抗原結合コンストラクト
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
CA3091683A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CA3089333C (en) * 2018-03-26 2023-10-10 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3107186A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
US20210284732A1 (en) 2018-07-31 2021-09-16 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
PE20211400A1 (es) 2018-08-03 2021-07-27 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3
KR20210086623A (ko) 2018-09-25 2021-07-08 하푼 테라퓨틱스, 인크. Ddl3 결합 단백질 및 사용 방법
EP4321530A3 (en) 2018-09-27 2024-05-22 Xilio Development, Inc. Masked cytokine polypeptides
AR116548A1 (es) 2018-09-28 2021-05-19 Amgen Inc Anticuerpos contra bcma soluble
EP3863670A1 (en) 2018-10-11 2021-08-18 Amgen Inc. Downstream processing of bispecific antibody constructs
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
CN112912716A (zh) 2018-10-23 2021-06-04 美国安进公司 用于实时预测的拉曼光谱模型的自动校准和自动维护
KR20210087472A (ko) * 2018-11-01 2021-07-12 산동 뉴 타임 파마슈티칼 코., 리미티드. 이중 특이성 항체 및 그 용도
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
TW202043253A (zh) 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
EP3927747A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020226893A1 (en) 2019-02-21 2021-09-23 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP2022537650A (ja) 2019-06-13 2022-08-29 アムジエン・インコーポレーテツド 生物製剤の製造における自動化された生物量に基づく灌流制御
WO2021050640A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
TW202132340A (zh) 2019-11-04 2021-09-01 美商安進公司 治療白血病之方法
EP3819007B1 (en) 2019-11-11 2024-07-10 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
TW202128767A (zh) 2019-12-13 2021-08-01 美商建南德克公司 抗ly6g6d抗體及其使用方法
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
CA3180321A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
TW202221023A (zh) * 2020-08-14 2022-06-01 日商中外製藥股份有限公司 單臂抗原結合分子及其用途
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
IL302597A (en) 2020-11-06 2023-07-01 Amgen Inc Constructive polypeptide binds to CD3
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
JP2023549116A (ja) 2020-11-06 2023-11-22 アムジエン・インコーポレーテツド 選択性が増大した多標的二重特異性抗原結合分子
WO2022103781A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
HUP2100038A1 (hu) * 2021-02-03 2022-08-28 Richter Gedeon Nyrt Mutáltatott rekombináns ACE2-Fc fúziós fehérjék COVID-19 fertõzések kezelésére
EP4305048A1 (en) 2021-03-10 2024-01-17 Amgen Inc. Methods for purification of recombinant proteins
JP2024509878A (ja) 2021-03-10 2024-03-05 アムジエン・インコーポレーテツド パラレルクロマトグラフィーシステム及び方法
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
CN113337514B (zh) * 2021-08-05 2021-10-29 卡瑞济(北京)生命科技有限公司 Tcr表达构建体以及其制备方法和用途
EP4416180A1 (en) * 2021-10-15 2024-08-21 CytomX Therapeutics, Inc. Activatable polypeptide complex
WO2023076318A1 (en) 2021-10-27 2023-05-04 Amgen Inc. Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
KR20240099407A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
WO2023164286A1 (en) 2022-02-28 2023-08-31 Xilio Development, Inc. Engineered cd122 compositions and methods thereof
US20230365641A1 (en) 2022-02-28 2023-11-16 Xilio Development, Inc. Targeted cytokines and methods of use thereof
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
TW202417474A (zh) 2022-07-15 2024-05-01 美商艾希利歐發展股份有限公司 經改造之可裂解載體及其使用方法
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
SI1071752T1 (en) * 1998-04-21 2003-12-31 Micromet Ag CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
CN1195779C (zh) * 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
KR101329843B1 (ko) * 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
EP1629012B1 (en) * 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2006379B1 (en) * 2006-03-23 2016-08-31 Tohoku University High functional bispecific antibody
CN101687915B8 (zh) * 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
KR101626988B1 (ko) * 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
BRPI0809594A2 (pt) * 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
EP2069401A4 (en) * 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2224954B1 (en) * 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2237797A4 (en) * 2008-01-03 2012-11-07 Scripps Research Inst TARGETING ANTIBODIES BY MODULAR RECOGNITION DOMAIN
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
PT2352763E (pt) * 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
US20130011401A1 (en) * 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
UA123257C2 (uk) * 2010-02-24 2021-03-10 Іммуноджен, Інк. Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
TWI838039B (zh) * 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UA113403C2 (xx) * 2011-04-01 2017-01-25 Спосіб підвищення ефективності folr1 терапії раку
JP2014514314A (ja) * 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013055809A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
SG11201403444UA (en) 2011-12-21 2014-07-30 Amgen Inc Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES

Also Published As

Publication number Publication date
US20230212297A1 (en) 2023-07-06
AU2014228829B2 (en) 2019-01-17
CR20150573A (es) 2015-11-19
AU2014228829A1 (en) 2015-09-10
AP2015008773A0 (en) 2015-09-30
MX2015012187A (es) 2016-04-15
EA201591814A1 (ru) 2016-03-31
US11753475B2 (en) 2023-09-12
US20180230220A1 (en) 2018-08-16
MA38400A1 (fr) 2017-09-29
WO2014144722A3 (en) 2014-11-06
WO2014144722A2 (en) 2014-09-18
JP6732988B2 (ja) 2020-07-29
TN2015000379A1 (en) 2017-01-03
PH12015502083A1 (en) 2016-01-18
US20190002568A1 (en) 2019-01-03
JP6535654B2 (ja) 2019-06-26
US20140302037A1 (en) 2014-10-09
PE20151998A1 (es) 2016-02-03
US20160145340A1 (en) 2016-05-26
JP2016516056A (ja) 2016-06-02
EP2970477B1 (en) 2023-10-04
BR112015023431A2 (pt) 2017-11-28
CA2902961C (en) 2023-08-01
EP2970477A2 (en) 2016-01-20
JP2019151634A (ja) 2019-09-12
MX2021010416A (es) 2021-09-14
CA2902961A1 (en) 2014-09-18
CL2015002756A1 (es) 2016-04-15
KR20150139531A (ko) 2015-12-11
CN105229031A (zh) 2016-01-06
IL241354A0 (en) 2015-11-30
HK1214275A1 (zh) 2016-07-22

Similar Documents

Publication Publication Date Title
AP2015008773A0 (en) Bispecific bivalent scfv-fc molecules
IL269528A (en) Anti- FCRH5 antibodies
GB201311487D0 (en) Bispecific molecules
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
PL3049439T3 (pl) Bispecyficzne nanociała
GB201319161D0 (en) Multivalent antigen-binding protein molecules
GB201322583D0 (en) Antibodies
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
PL3019532T3 (pl) Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii
IL245488A0 (en) Anti- ccl17 antibodies
GB201302878D0 (en) Modified igG molecules
GB201318283D0 (en) Antibodies